Skip to content
10-Q

Quarterly Report

AN2 Therapeutics, Inc. ANTX

0000950170-25-070358

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 30.18M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $19.99M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $21.35M
Total Liabilities Q1 2025 · Mar 31, 2025 $8.01M
Total Liabilities Q1 2025 · Dec 31, 2024 $10.24M
Current Assets Q1 2025 · Mar 31, 2025 $69.56M
Current Assets Q1 2025 · Dec 31, 2024 $86.26M
Total Assets Q1 2025 · Mar 31, 2025 $81.34M
Total Assets Q1 2025 · Dec 31, 2024 $92.09M
Shares Diluted Q1 2025 · Mar 31, 2024 29.76M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$17.59M
Stockholders Equity Q1 2025 · Mar 31, 2024 $110.6M
Stockholders Equity Q1 2025 · Dec 31, 2023 $124.7M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.56
Eps Basic Q1 2025 · Mar 31, 2024 −$0.56
Sga Expense Q1 2025 · Mar 31, 2024 $3.64M
Rd Expense Q1 2025 · Mar 31, 2024 $14.66M
Net Income Q1 2025 · Mar 31, 2024 −$16.62M
Operating Income Q1 2025 · Mar 31, 2024 −$18.3M